

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/506,554	1st Named Inventor: Paul Robert Whittamore
371 Filing Date: 09/01/2004	Attorney Docket No.: 100663-1P US
Examiner: Nolan, Jason Michael	Group Art Unit: 1626
Customer No.: 44992	Confirmation No.: 1655
Title: Indolamid Derivatives Which Possess Glycogenophosphorylase Inhibitory Activity	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Supplemental Information Disclosure Statement

Sir:

Applicants are submitting a supplemental information disclosure statement. This statement lists certain new references and certain references which were disclosed previously. Four of these references are being resubmitted because although the correct documents were sent in March 2005 and appear on PAIR, there were typographical errors in the corresponding bibliographic details on the SB08. Applicants wish the correct bibliographic details to appear on the front page of any patent resulting from this application.

Specifically the following errors have been corrected:

- 1) JP 2001247565 was incorrectly listed as JP021247565. The Applicant should have been listed as Pfizer Prod Inc. The correct publication date is 11th September 2001. Applicants are submitting both the JP application and an English abstract at this time.
- 2) J Het Chem, (1974), 11(2), 143-150 - the journal title was missing from the SB08.
- 3) Teague et al, Diabetes, Vol 53 supp 2, A365, 1521-P - on the SB08 suppl 1 was listed instead of 2. The year was also missing.
- 4) Vertigan et al, Diabetologia, vol 47, supp 1, A214, 589 - The journal was listed as Diabetes instead of Diabetologia. The year was also missing.

Furthermore, attached to the notice of allowance dated 04/05/2006 the Examiner had included an annotated SB08 indicating that he had considered some of references listed, but some references had been crossed off the SB08. Applicants telephoned the Examiner on the 11th April and understand that these had been crossed off because Applicants had failed to indicate the year of the reference on the SB08. Applicants are resubmitting these references at this time (two of which are 3) and 4) above) and are re-listing them with their years indicated.

The Examiner is respectfully requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed SB08.

Respectfully submitted,

/Lucy Padget/

Name: Lucy Padget
Dated: April 14th, 2006
Reg. No.: L0074
Phone No.: 781-839-4182
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451